menu
    • menu
    [{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Organovo Holdings","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Tarveda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"OnCusp Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Mutabilis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Claris Bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Oremepermin Alpha","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Solution","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"NMD PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"FXR314","moa":"FXR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Eli Lilly"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Asgard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Muna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Organovo Holdings","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Nuvig Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Organovo Holdings","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Stargazer Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Organovo Holdings","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"AvenCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"AVC-101","moa":"||CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"NodThera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"MapLight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Kivu Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"KIVU-107","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Organovo Holdings","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Organovo Holdings","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Myricx Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"MYX2468","moa":"N-Myristoyltransferase","graph1":"Oncology","graph2":"Preclinical","graph3":"Organovo Holdings","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Organovo Holdings \/ Organovo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Hemab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Organovo Holdings","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Organovo Holdings \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Organovo Holdings \/ Organovo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals by Organovo Holdings

    Menu

    Organovo Holdings

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $60.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Pays $10M Upfront for Organovo’s FXR Agonist Program

                            Details : Through the acquisition, Lilly will leverage FXR program of Organovo, which includes FXR314, it is being evaluated for the treatment of Inflammatory Bowel Disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            February 25, 2025

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $60.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Kivu Bioscience

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kivu Bioscience Raises $92M to Advance Antibody-Drug Conjugates

                            Details : The financing will aims to support the clinical development of multiple antibody-drug conjugate (ADC) programs, which include KIVU-107. It is being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Kivu Bioscience

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AvenCell Therapeutics

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings

                            Details : The proceeds will accelerate AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, including AVC-101, for a wide range of hematologic malignancies and auto-immune diseases.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AvenCell Therapeutics

                            Deal Size : $112.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Jonestrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

                            Details : Proceeds will advance the company's pipeline, including lead molecule FXR314, targeting inflammatory bowel disease and applications in metabolic liver disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Jonestrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MYX2468

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Myricx Bio

                            Deal Size : $114.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Novo Holdings Leads £90M Financing for Myricx Bio ADC Payload Class

                            Details : The financing aims to fund the advancement of Myricx's proprietary pipeline of N-Myristoyltransferase inhibitor MYX2468 for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            July 07, 2024

                            Lead Product(s) : MYX2468

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Myricx Bio

                            Deal Size : $114.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organovo Reveals Positive Phase 2 Results for FXR314 in MASH

                            Details : The company’s lead molecule, FXR314, the non-steroidal, non-bile acid FXR agonist, is being developed for the treatment of metabolic function-associated steatohepatitis (MASH).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 15, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CUSP06

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : OnCusp Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            OnCusp Raises $100 Million in Oversubscribed Series A Financing for Cancer Assets

                            Details : The proceeds will be used to advance CUSP06, the company's antibody drug conjugate (ADC) targeting CDH6 against cancer, toward clinical proof-of-concept.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : CUSP06

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : OnCusp Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oremepermin Alpha

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Recipient : Claris Bio

                            Deal Size : $57.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Claris Bio Prepares for Next Stage with New Investor and Late-Stage Data in 2024

                            Details : The net proceeds will be used to advance CSB-001 (oremepermin alfa), a topical ocular biologic solution of dHGF, targets complete healing of the cornea surface in eyes with Neurotrophic Keratopathy.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Oremepermin Alpha

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Claris Bio

                            Deal Size : $57.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMD670

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : NMD PHARMA

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

                            Details : The proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : NMD670

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : NMD PHARMA

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : MapLight Therapeutics

                            Deal Size : $225.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System...

                            Details : The net funding will advance ML-007C-MA, a novel M1/M4 muscarinic agonist agent combined with a precision matched peripheral muscarinic antagonist, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis in 2024.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : MapLight Therapeutics

                            Deal Size : $225.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth